Blouin D, Murray M A, Beard R W
Br J Obstet Gynaecol. 1976 Sep;83(9):711-5. doi: 10.1111/j.1471-0528.1976.tb00918.x.
The reported growth-promoting effects of the beta-sympathomimetic compound, ritodrine, have been investigated. The carbohydrate tolerance of eight pregnant women was found to be unaffected by treatment with oral ritodrine over a ten-week period. A further observation that the carbohydrate metabolism of the newborn infants of these women was within normal limits tends to discount possibility that any growth-promoting action ritodrine may have on the fetus is mediated through a diabetogenic effect on the mother.
已对β-拟交感神经化合物利托君的促生长作用进行了研究。发现8名孕妇口服利托君治疗10周后，其糖耐量未受影响。进一步观察发现，这些妇女的新生儿碳水化合物代谢在正常范围内，这倾向于排除利托君对胎儿可能具有的任何促生长作用是通过对母亲产生致糖尿病效应来介导的可能性。
